Healthcare Capital Markets in 2026: The Biotech IPO Thaw

Introduction

Healthcare capital markets spent four years in a biotech IPO freeze. The 2021 peak brought close to 100 biotech listings, the following three years produced a fraction of that, and 2025 managed just 11 by BioPharma Dive's count. Then the window reopened, and decisively: by mid-August 2026, Dealogic had logged 21 US biotech IPOs raising $7.85 billion, the strongest run since 2021, per Mergermarket's analysis of the 2026 revival. This article covers what reopened the window, what investors now demand, why follow-ons dwarf IPO volume, and what the SPAC era left behind. The throughline for healthcare bankers: for a private biotech, ECM and M&A advisory are now one conversation.

Six biotechs priced IPOs in the first quarter at a median of $287.5 million, and the $1.7 billion they raised was the most of any quarter since 2021. Deal sizes then climbed further: Kailera Therapeutics raised $625 million in April and Parabilis Medicines $670 million in June, both topping the record Moderna had held since 2018, and 11 of the 13 venture-backed biotechs that priced in the first half raised at least $250 million each (BioPharma Dive's mid-year review).

Three forces explain the turn. First, aftermarket performance: most of the first-half class traded at or above its offer price by June, led by Veradermics, which rose more than fivefold after positive hair-loss data. Second, pharma demand for late-stage assets ahead of the patent cliff gives investors a credible exit even if a stock stalls. Third, M&A capital recycling, covered below, put cash back with the funds that buy biotech IPOs.

The rally peaked in August, when the XBI biotech index hit a five-year high near $170; it then slid to about $158 by quarter-end, per William Blair's Q3 2026 recap, as the Fed raised rates by 25 basis points on September 16, its first hike since 2023. BioPharma Dive's analysis of the pullback adds disappointing trial readouts and fewer public-company buyouts, which slowed the recycling loop. Issuance held up: Renaissance Capital's 3Q 2026 review counts nine biotech IPOs raising $2.4 billion, making healthcare the busiest sector by deal count, while William Blair tallies $2.7 billion, with seven of the nine priced at the top of the range or above.

Phase 2+ Data Threshold

The informal standard in the post-2021 biotech IPO market that a company should have positive Phase 2 clinical data, and increasingly Phase 2b or Phase 3 data, before it can go public. In 2020-2021, preclinical and Phase 1 companies listed on mechanism-of-action novelty and early safety data; today investors want demonstrated efficacy in a relevant patient population and a clear path to registrational trials, which shrinks the IPO-eligible pool and keeps biotechs private longer.

The threshold held through the rebound: almost every first-half IPO had a drug in Phase 2 or later, and preclinical companies stayed largely shut out. Exceptions such as Scribe Therapeutics, with a lead program just entering the clinic, were rare. Pricing showed the preference: platform stories such as Eikon Therapeutics and Generate Biomedicines traded below their offer prices by the end of the first quarter, while single-asset stories with near-term data were rewarded.

Biotech M&A and the IPO market are linked in two ways, and 2026 has shown both.

For healthcare bankers, this makes the IPO-versus-sale decision a core advisory question. A company with compelling Phase 2 data and one obvious acquirer may be better served by a sell-side process; one with a multi-asset pipeline and years of trials ahead usually needs public capital.

IPOs are the headline but the smallest slice of biotech equity issuance. The same Dealogic data show 289 follow-on offerings worth $33.35 billion by mid-August, second only to the 2020 record, plus 38 convertible deals totaling $9.81 billion, an all-time high. That is more than four dollars of follow-on capital for every IPO dollar. Public biotechs with fresh clinical data raise quickly through overnight deals and PIPEs, or steadily through ATM programs, all covered in the biotech capital markets toolkit.

The SPAC aftermath still shapes the bar for new listings. The 2020-2021 boom took dozens of early-stage healthcare companies public through blank-check mergers, skipping an underwritten IPO, and many now trade far below the $10 trust value of their deals. Regulators responded: the SEC's January 2024 SPAC rules made target companies co-registrants on the merger filing and removed the litigation safe harbor for SPAC projections, bringing de-SPAC liability close to IPO standards (our ECM guide breaks down the rules). With that route largely closed, the IPO is again the main door to public markets, full data bar included.

For healthcare bankers, 2026 rewards fluency in both ECM and M&A, because the biotech clients who matter most weigh both paths at once. The window is open to a narrower set of companies than in 2021, and the third-quarter pullback showed how quickly it tightens when rates and clinical data turn.

The next article decodes the key themes from JPM 2026, the healthcare industry's most important annual conference.